Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilona Bebenek

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Toxicological Sciences : an Official Journal of the Society of Toxicology|April 21, 2009
Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genesSudheer R Beedanagari, Ilona Bebenek, Peter Bui, et al.
International Journal of Toxicology|March 1, 2022
Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case StudiesVijay P Kale, Ilona Bebenek, Hanan Ghantous, et al.
Regulatory Toxicology and Pharmacology : RTP|February 6, 2023
Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologiesAmy M Avila, Ilona Bebenek, Donna L Mendrick, et al.
International Journal of Toxicology|August 9, 2020
Drug Development 101: A PrimerLorrene A Buckley, Ilona Bebenek, Paul D Cornwell, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|November 4, 2021
COVID-19 Therapeutics and Vaccines: A Race to Save LivesIlona Bebenek, Roy Bannister, John Dubinion, et al.
International Journal of Toxicology|November 13, 2025
FDA/CDER/OND Experience With New Approach Methodologies (NAMs)Jia Yao, Jackye Peretz, Ilona Bebenek, et al.
Regulatory Toxicology and Pharmacology : RTP|April 24, 2020
An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)Amy M Avila, Ilona Bebenek, Jessica A Bonzo, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Toxicological Sciences : an Official Journal of the Society of Toxicology|April 21, 2009
Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genesSudheer R Beedanagari, Ilona Bebenek, Peter Bui, et al.
International Journal of Toxicology|March 1, 2022
Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case StudiesVijay P Kale, Ilona Bebenek, Hanan Ghantous, et al.
Regulatory Toxicology and Pharmacology : RTP|February 6, 2023
Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologiesAmy M Avila, Ilona Bebenek, Donna L Mendrick, et al.
International Journal of Toxicology|August 9, 2020
Drug Development 101: A PrimerLorrene A Buckley, Ilona Bebenek, Paul D Cornwell, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|November 4, 2021
COVID-19 Therapeutics and Vaccines: A Race to Save LivesIlona Bebenek, Roy Bannister, John Dubinion, et al.
International Journal of Toxicology|November 13, 2025
FDA/CDER/OND Experience With New Approach Methodologies (NAMs)Jia Yao, Jackye Peretz, Ilona Bebenek, et al.
Regulatory Toxicology and Pharmacology : RTP|April 24, 2020
An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)Amy M Avila, Ilona Bebenek, Jessica A Bonzo, et al.
Pageof 1